CORK, IRELAND. November 9th, 2026 – Applied Biopharm Consulting Ltd has announced the filing of its first patent application, marking an important milestone in the company’s expanding research and development activities in advanced biomolecular engineering and biotechnology.
The patent application relates to proprietary innovations developed through the company’s internal research programme, with an initial focus on technologies designed to improve the targeted delivery of therapeutics to skeletal muscle cells. The research includes the computational design and experimental evaluation of novel muscle-targeting ligands, with potential applications in gene therapy and the development of new treatment approaches for Duchenne muscular dystrophy and other inherited neuromuscular disorders.
Building on an initial feasibility grant supported by the Local Enterprise Office Cork North & West in 2024, Applied Biopharm Consulting has established a research programme combining artificial intelligence (AI), structural bioinformatics and computational molecular modelling with experimental laboratory studies.
In 2026, the company secured an Intellectual Property (IP) Start Grant under Enterprise Ireland’s IP Strategy initiative, supporting specialist patent advisory services and the development of a formal intellectual property strategy. The company also established a research collaboration with the Pharmaceutical and Molecular Biotechnology Research Centre (PMBRC) at South East Technological University (SETU), supported through the Enterprise Ireland Innovation Voucher scheme, to undertake cell-based experimental studies to validate aspects of the company’s computational research programme.
These activities have contributed to the development of the company’s first proprietary technology programme and the progression of its research towards potential commercial applications.
Dr Anthony Newcombe, Managing Director of Applied Biopharm Consulting Ltd, commented: “Our first patent filing represents an important milestone in the development of our proprietary muscle-targeting technologies. By combining computational molecular design with experimental research, we are developing innovative approaches to targeted therapeutic delivery, with an initial focus on skeletal muscle.”
The patent filing represents an important step in establishing a portfolio of proprietary biotechnology innovations, supporting future research activities and creating opportunities for potential industry partnerships and commercial development.
Applied Biopharm Consulting’s investment in biotechnology research complements its established international consulting activities, which provide specialist expertise in GMP compliance, Regulatory CMC, Manufacturing Science & Technology (MSAT), Quality Assurance and technology transfer to pharmaceutical and biotechnology organisations worldwide.
ENDS